Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives $68.29 Consensus Price Target from Brokerages

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has earned a consensus recommendation of “Moderate Buy” from the eighteen research firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and sixteen have given a buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $65.7647.

Several research firms recently commented on RARE. Robert W. Baird cut their target price on shares of Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating for the company in a research note on Tuesday, December 30th. Guggenheim decreased their target price on Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating on the stock in a report on Monday, January 5th. Wells Fargo & Company reduced their target price on Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating for the company in a report on Tuesday, December 30th. Canaccord Genuity Group decreased their price target on Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a “buy” rating for the company in a research report on Wednesday, February 18th. Finally, Bank of America cut their price objective on Ultragenyx Pharmaceutical from $72.00 to $58.00 and set a “buy” rating on the stock in a report on Friday, January 2nd.

Ultragenyx Pharmaceutical Trading Down 2.3%

NASDAQ RARE opened at $21.71 on Tuesday. The company has a 50-day moving average price of $23.06 and a two-hundred day moving average price of $28.88. Ultragenyx Pharmaceutical has a 52 week low of $18.41 and a 52 week high of $42.37. The stock has a market cap of $2.10 billion, a price-to-earnings ratio of -3.72 and a beta of 0.16.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.09). Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 1,024.42%. The business had revenue of $207.28 million for the quarter, compared to the consensus estimate of $199.60 million. During the same period last year, the firm posted ($1.39) EPS. The business’s quarterly revenue was up 25.5% on a year-over-year basis. As a group, equities research analysts expect that Ultragenyx Pharmaceutical will post -5.18 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider John Richard Pinion sold 10,029 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $22.80, for a total transaction of $228,661.20. Following the sale, the insider owned 110,026 shares in the company, valued at $2,508,592.80. The trade was a 8.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Howard Horn sold 8,409 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $22.70, for a total transaction of $190,884.30. Following the completion of the sale, the chief financial officer owned 86,669 shares of the company’s stock, valued at approximately $1,967,386.30. This trade represents a 8.84% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 104,958 shares of company stock valued at $2,394,858 over the last 90 days. 5.50% of the stock is owned by corporate insiders.

Institutional Trading of Ultragenyx Pharmaceutical

Several hedge funds and other institutional investors have recently modified their holdings of RARE. Flax Pond Capital LLC purchased a new position in shares of Ultragenyx Pharmaceutical during the fourth quarter valued at $1,293,000. Caitong International Asset Management Co. Ltd raised its position in Ultragenyx Pharmaceutical by 1,116,754.5% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 122,854 shares of the biopharmaceutical company’s stock valued at $2,826,000 after buying an additional 122,843 shares during the period. Alberta Investment Management Corp purchased a new stake in Ultragenyx Pharmaceutical in the 4th quarter worth about $883,000. Mercer Global Advisors Inc. ADV boosted its position in Ultragenyx Pharmaceutical by 17.1% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 13,965 shares of the biopharmaceutical company’s stock worth $321,000 after acquiring an additional 2,036 shares during the period. Finally, Krensavage Asset Management LLC purchased a new position in Ultragenyx Pharmaceutical during the 4th quarter valued at about $3,442,000. Institutional investors and hedge funds own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical News Roundup

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Late‑stage win — Ultragenyx reported positive 36‑week Phase 3 results for DTX301 (AAV8 gene therapy) in OTC deficiency showing sustained ammonia reductions and improved metabolic control, a clear clinical proof‑point that could support a regulatory filing and a large addressable market for a first‑in‑class therapy. Article Title
• Neutral Sentiment: Analyst action — JPMorgan materially lowered its price target from $120 to $74 but kept an Overweight rating, signalling confidence in the longer‑term thesis while trimming upside assumptions; this tempers but does not reverse buy‑side optimism. Article Title
• Negative Sentiment: Multiple securities‑class action notices — Several law firms (Rosen, Pomerantz, Schall, DJS, Levi & Korsinsky, others) have filed or solicited lead‑plaintiff applications alleging securities law violations for purchases between Aug 3, 2023 and Dec 26, 2025; April 6, 2026 is the commonly cited lead‑plaintiff deadline. The wave of litigation increases headline risk, potential legal costs, and near‑term selling pressure. Article Title

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.